M Ailenberg1,2,3, C Di Ciano-Oliveira1,2,3, K Szaszi1,2,3, Q Dan1,2,3, M Rozycki1,2,3, A Kapus1,2,3, O D Rotstein1,2,3. 1. Departments of Surgery, St. Michael's Hospital, Toronto, ON, Canada. 2. University of Toronto, Toronto, ON, Canada. 3. Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND AND PURPOSE: Dynasore has been used extensively as an inhibitor of clathrin-mediated endocytosis. While studying the role of endocytosis in LPS-induced signalling events, we discovered that dynasore itself induced activation of NF-κB, independently of its effects on endocytosis and without involving the Toll-like receptor 4 signalling pathways. The purpose of this study was to characterize this novel effect and to explore the underlying mechanism of action. EXPERIMENTAL APPROACH: We utilized gel electrophoresis, microscopy, gene knockdown and luciferase-based promoter activity to evaluate the effect of dynasore on cell signalling pathways and to delineate the mechanisms involved in its effects, KEY RESULTS: Dynasore activated the NF-κB and IFN-β pathways by activating mitochondrial antiviral signalling protein (MAVS). We showed that MAVS is activated by NOX/Rac and forms high molecular weight aggregates, similar to that observed in response to viral infection. We also demonstrated that dynasore-induced activation of JNK occurs downstream of MAVS and is required for activation of NF-κB and IFN-β. CONCLUSION AND IMPLICATIONS: These findings demonstrate a novel effect of dynasore on cell signalling. We describe a novel Rac1-, ROS- and MAVS-mediated signalling cascade through which dynasore dramatically activates NF-κB, mimicking the viral induction of this key inflammatory signalling pathway. Our results call attention to the need for a broader interpretation of results when dynasore is used in its traditional fashion as an inhibitor of clathrin-mediated endocytosis. These results suggest the intriguing possibility that dynasore or one of its analogues might be of value as an antiviral therapeutic strategy or vaccine adjuvant.
BACKGROUND AND PURPOSE:Dynasore has been used extensively as an inhibitor of clathrin-mediated endocytosis. While studying the role of endocytosis in LPS-induced signalling events, we discovered that dynasore itself induced activation of NF-κB, independently of its effects on endocytosis and without involving the Toll-like receptor 4 signalling pathways. The purpose of this study was to characterize this novel effect and to explore the underlying mechanism of action. EXPERIMENTAL APPROACH: We utilized gel electrophoresis, microscopy, gene knockdown and luciferase-based promoter activity to evaluate the effect of dynasore on cell signalling pathways and to delineate the mechanisms involved in its effects, KEY RESULTS:Dynasore activated the NF-κB and IFN-β pathways by activating mitochondrial antiviral signalling protein (MAVS). We showed that MAVS is activated by NOX/Rac and forms high molecular weight aggregates, similar to that observed in response to viral infection. We also demonstrated that dynasore-induced activation of JNK occurs downstream of MAVS and is required for activation of NF-κB and IFN-β. CONCLUSION AND IMPLICATIONS: These findings demonstrate a novel effect of dynasore on cell signalling. We describe a novel Rac1-, ROS- and MAVS-mediated signalling cascade through which dynasore dramatically activates NF-κB, mimicking the viral induction of this key inflammatory signalling pathway. Our results call attention to the need for a broader interpretation of results when dynasore is used in its traditional fashion as an inhibitor of clathrin-mediated endocytosis. These results suggest the intriguing possibility that dynasore or one of its analogues might be of value as an antiviral therapeutic strategy or vaccine adjuvant.
Authors: Michal Caspi Tal; Miwa Sasai; Heung Kyu Lee; Brian Yordy; Gerald S Shadel; Akiko Iwasaki Journal: Proc Natl Acad Sci U S A Date: 2009-02-05 Impact factor: 11.205
Authors: Mark T Howes; Matthew Kirkham; James Riches; Katia Cortese; Piers J Walser; Fiona Simpson; Michelle M Hill; Alun Jones; Richard Lundmark; Margaret R Lindsay; Delia J Hernandez-Deviez; Gordana Hadzic; Adam McCluskey; Rumasia Bashir; Libin Liu; Paul Pilch; Harvey McMahon; Phillip J Robinson; John F Hancock; Satyajit Mayor; Robert G Parton Journal: J Cell Biol Date: 2010-08-16 Impact factor: 10.539
Authors: Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Menachem Ailenberg; Andras Kapus; Chung Ho Leung; Katalin Szaszi; Philip Williams; Caterina diCiano-Oliveira; John C Marshall; Ori D Rotstein Journal: Shock Date: 2022-07-19 Impact factor: 3.533
Authors: Indra Sarabia; Camille L Novis; Amanda B Macedo; Hiroshi Takata; Racheal Nell; Juyeon C Kakazu; Robert L Furler; Binita Shakya; Heidi L Schubert; Christopher P Hill; Ana Beatriz DePaula-Silva; Adam M Spivak; Lydie Trautmann; Vicente Planelles; Alberto Bosque Journal: Front Immunol Date: 2021-06-14 Impact factor: 7.561
Authors: Arlek M González-Jamett; Ximena Baez-Matus; María José Olivares; Fernando Hinostroza; Maria José Guerra-Fernández; Jacqueline Vasquez-Navarrete; Mai Thao Bui; Pascale Guicheney; Norma Beatriz Romero; Jorge A Bevilacqua; Marc Bitoun; Pablo Caviedes; Ana M Cárdenas Journal: Sci Rep Date: 2017-07-04 Impact factor: 4.379